http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-110968-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ab29b52a19d65879e70b22bb846a2cf |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07G3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2018-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-110968-A2 |
| titleOfInvention | DERIVATIVES OF BENCYL GLYCOSIDE AND PHARMACEUTICAL COMPOSITION |
| abstract | Compounds are provided that have an inhibitory effect on the SGLT sodium dependent glucose cotransporter. Pharmaceutical compositions, methods of preparation of the compounds, synthetic intermediates and methods of using the compounds, independently or in combination with other therapeutic agents, to treat diseases and pathological conditions affected by the inhibition of SGLT. Claim 1: A compound having the formula (1), wherein A is a member selected from the group consisting of oxygen; sulfur; SW; SO₂; methylene optionally substituted with one or two substituents independently selected from halo, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl and C₃₋₆ cycloalkyloxy; 1,1-C₃₋₅ cycloalkylene optionally substituted with one or two substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl and C₃₋₆ cycloalkyloxy; and NRᵃ; V is a member selected from the group consisting of oxygen; sulfur; SW; SO₂; and a simple link; W is a member selected from the group consisting of C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₃₋₁₀ cycloalkylene and C₅₋₁₀ cycloalkenylene; where each alkylene, alkenylene, alkynylene, cycloalkylene and cycloalkenylene group of W is optionally partially or completely fluorinated and is optionally mono or disubstituted with identical or different substituents selected from chlorine, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, cycloalkyl C₃₋₆, C₃₋₆ cycloalkyloxy, C₅₋₁₀ cycloalkenyl and C₅₋₁₀ cycloalkenyloxy, and in the cycloalkylene and cycloalkenylene groups of W, one or two methylene groups are optionally independently replaced with each other by O, S, CO, SO, SO₂ or NRᵇ, and one or two methine groups of W are optionally replaced by N; X is (i) is a member selected from the group consisting of oxygen; sulfur; SW; and SO₂; or (ii) NRᵃ; when X is (i), Y is a member selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₅₋ cycloalkenyl ₁₀, (C₅₋₁₀ cycloalkenyl) C₁₋₃ alkyl, (C₃₋₁₀ cycloalkyl) C₂₋₄ alkenyl, C₃₋₆ cycloalkylmethyl, (C₅₋₁₀ cycloalkenyl), C₂₋₄ alkynyl, (C alquilo alkyloxy) , (C₂₋₄ alkenyloxy) C₁₋₃ alkyl, (C₃₋₁₀ cycloalkyloxy) C₁₋₃ alkyl, (C ciclo cycloalkenyloxy), (C₁₋₄ alkylamino) C₁₋₃ alkyl, di- (C₁ alkylamino ₋₆) C₁₋₃ alkyl, (C₁₋₆ alkyl) C₁₋₃ carbonylalkyl, (C₂₋₆ alkenyl) C₁₋₃ carbonylalkyl, (C₂₋₆ alkynyl) carbonylC₁₋₃ alkyl, (arylcarbonyl) C₁₋₃ alkyl, ( heteroarylcarbonyl) C₁₋₃ alkyl, (Cils alkylsulfonyl) C₁₋₃ alkyl, (C₂₋ alkenylsulfonyl ) C₁₋₃ alkyl, (C₂₋₆ alkynylsulfonyl) C₁₋₃ alkyl, (arylsulfonyl) C₁₋₃ alkyl, (heteroarylsulfonyl) C₁₋₃ alkyl, (C₁₋₆ alkyl) aminocarbonylalkyl C₁₋₃, (C₂₋₆ alkenyl) C₁₋₃ aminocarbonylalkyl, (C₂₋₆ alkynyl) aminocarbonylalkyl C₁₋₃, (arylaminocarbonyl) C₁₋₃ alkyl, (heteroarylaminocarbonyl) C₁₋₃ alkyl, (alkyl) C₁₋₆ carbonyl, (alkenyl) C₂₋₆ carbonyl, (alkynyl ) C₂₋₆ carbonyl, arylcarbonyl and heteroarylcarbonyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of Y are optionally partially or completely fluorinated and optionally are mono- or disubstituted with identical or different substituents selected from the group consisting of chlorine, hydroxy, C₁ alkyl ₋₃, C₁₋₃ alkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyloxy, C₅₋₁₀ cycloalkenyl, and NRᵇRᶜ, and in Y cycloalkyl and cycloalkenyl groups or portions, one or two methylene groups are optionally replaced independently of each other with O, S, CO, SO, SO₂ or NRᵇ, and one or two methylene groups are optionally replaced by N, where the heterocycle formed by said optional replacement is different from heteroaryl, and where when V is a member selected from the group consisting of oxygen, sulfur and a single bond and W is a member selected from the group consisting of C₁₋₆ alkylene, which Cileno nylene and C₂₋₆ alkynylene, then Y is different from C₁₋₆ alkyl; when X is (ii), Y is a member selected from the group consisting of C₁₋₆ alkylsulfonyl, C₂₋₆ alkenylsulfonyl, C₂₋₆ alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C₁₋₆ alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, (C₁₋₆ alkyl ) carbonyl, (alkenyl) C₂₋₆ carbonyl, (alkynyl) C₂₋₆ carbonyl, arylcarbonyl, heteroarylcarbonyl, (alkyl) aminocarbonyl C₁₋₆, (alkenyl) aminocarbonyl C₂₋₆, (alkynyl) aminocarbonyl C₂₋₆, arylaminocarbonyl, heteroarylaminocarbonyl , (C₁₋₆ alkylsulfonyl) C₁₋₃ alkyl, (C alkenylsulfonyl) C₁₋₃ alkyl, (C alkynylsulfonyl) C alquilo alkyl, (arylsulfonyl) C₁₋₃ alkyl, (heteroarylsulfonyl) C₁₋₃ alkyl, (C₁₋₆ alkylsulfinyl) C₁₋₃ alkyl, (arylsulfinyl) C₁₋₃ alkyl, (heteroarylsulfinyl) C₁₋₃ alkyl, (alkyl) aminocarbonyl C₁₋₆alkyl, (C₂₋₆ alkenyl) aminocarbonyl-C₁₋₃ alkyl , (alq uin-Cin) aminocarbonyl-C alquilo alkyl, (arylaminocarbonyl) C alquilo alkyl and (heteroarylaminocarbonyl) C₁₋₃ alkyl; wherein the alkyl, alkenyl and alkynyl portions of Y are optionally partially or completely fluorinated, and when Rᵃ is H or (C) alkyl) carbonyl, then Y is different from (C) alkyl) or arylcarbonyl; Z is a member selected from the group consisting of oxygen; sulfur; SW; SO₂; 1,1-cyclopropylene; carbonyl; and methylene optionally substituted with one or two substituents independently selected from the group consisting of halo, hydroxy, C₁₋₆ alkyl, C alco alkoxy, C₃₋₆ cycloalkyl and C₃₋₆ cycloalkyloxy; R¹ is a member selected from the group consisting of hydrogen, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, (C₃₋₁₀ cycloalkyl) C₁₋₃ alkyl, (C₂₋₄ alkenyl ) C₁₋₃ alkyloxy, (C₂₋₄ alkynyl) C₁₋₃ alkyloxy, (C₃₋₁₀ cycloalkyl) C₂₋₄ alkenyl, C₃₋₆ cycloalkylmethyl, (C₃₋₁₀ cycloalkyloxy), C₁₋₃ alkyl, C₅₋₁₀ cycloalkenyl, ( C₅₋₁₀ cycloalkenyl) C₁₋₃ alkyl, (C₁₋₄ alkyloxy) C₁₋₃ alkyl, (C₁₋₄ alkylamino) C₁₋₃ alkyl, di- (C₁₋₃ alkylamino) C₁₋₃ alkyl, aryl, heteroaryl, ( C₁₋₄ alkyl) carbonyl, arylcarbonyl, heteroarylcarbonyl, hydroxycarbonyl, aminocarbonyl, (C) alkyl aminocarbonyl, di- (alkyl) aminocarbonyl C₁₋₃, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl , piperazin-1-ylcarbonyl, 4- (C₁₋₄ alkyl) piperazin-1-ylcarbonyl, (alkyloxy) carb C₁₋₄ onyl, amino, C₁₋₄ alkylamino, di- (alkyl) amino C₁₋₃, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4- (alkyl C₁₋₄) piperazin-1-yl, (C) alkylcarbonylamino, arylcarbonylamino, C₁₋₄ alkylsulfonylamino, arylsulfonylamino, heteroarylcarbonylamino, C₁₋₆ alkyloxy, C₃₋₁₀ cycloalkyloxy, aryloxy, heteroaryloxy, (aryl) ) C₁₋₃ alkyloxy, (heteroaryl) C₁₋₃ alkyloxy, C₁₋₄ alkylsulfanyl, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₃₋₁₀ cycloalkylsulfanyl, C₃₋₁₀ cycloalkylsulfinyl, C₅₋₁₀ cycloalkylsulfonyl, C₅₋₁₀ cycloalkenylsulfanyl, cycloalkenylsulfinyl C₅₋₁₀, C₅₋₁₀ cycloalkenylsulfonyl, arylsulfanyl, arylsulfinyl, arylsulfonyl, hydroxy, cyano and nitro; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of R¹ are optionally partially or completely fluorinated and are optionally mono- or disubstituted with identical or different substituents selected from the group consisting of chlorine, hydroxy, C₁ alkoxy ₋₃ and C₁₋₃ alkyl, and in the cycloalkyl and cycloalkenyl groups or portions of R¹, one or two methylene groups are optionally independently replaced with each other by O, S, CO, SO or SO en, and in the groups or portions N-heterocycloalkyl of R¹, a methylene group is optionally replaced with CO or SO₂; R² is a member selected from the group consisting of hydrogen, halo, hydroxy, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, C₅₋₁₀ cycloalkenyl, C₁₋₄ alkyloxy, C₃₋₁₀ cycloalkyloxy , cyano and nitro; where the alkyl and cycloalkyl groups or portions of R² are optionally mono- or polysubstituted with fluorine, or in the case that R¹ and R² are joined by adjacent C atoms of the phenyl ring, R¹ and R² are optionally joined together to form a bridge C₃₋₅ alkylene, C₃₋₅ alkenylene or butadienylene, which is optionally partially or completely fluorinated and optionally mono- or disubstituted with identical or different substituents selected from chlorine, hydroxy, C₁₋₃ alkoxy and C₁₋₃ alkyl, and where one or two methylene groups are optionally independently replaced with O, S, CO, SO, SO₂ or NRᵇ, and where one or two methine groups may optionally be replaced with N; R³ is a member selected from the group consisting of hydrogen, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, (C₃₋₁₀ cycloalkyl) C₁₋₃ alkyl, C₅₋₁₀ cycloalkenyl, (C₅₋₁₀ cycloalkenyl) C₁₋₃ alkyl, (C₁₋₄ alkyloxy) C₁₋₃ alkyl, (C ciclo cycloalkyloxy), (C₁₋₄ alkylamino) C₁₋₃ alkyl, di- (C₁₋ alkylamino ₃) C₁₋₃ alkyl, (C₃₋₁₀ cycloalkyl) C₂₋₄ alkenyl, C₃₋₆ cycloalkylmethylmethyl, aryl, heteroaryl, (C) alkyl) carbonyl, arylcarbonyl, heteroarylcarbonyl, aminocarbonyl, (C₁₋₄ alkyl) aminocarbonyl, di - (C₁₋₃ alkyl) aminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4- (C₁₋₄ alkyl) piperazin-1-ylcarbonyl, hydroxycarbonyl, ( C₁₋₄ alkyloxy) carbonyl, C₁₋₄ alkylamino, di- (C₁₋₃ alkyl) amino, pyrrolidin-1-yl , piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4- (C₁₋₄ alkyl) piperazin-1-yl, (C₁₋₄ alkyl) carbonylamino, arylcarbonylamino, heteroarylcarbonylamino, C₁₋ alkylsulfonylamino ₄, arylsulfonylamino, C₁₋₆ alkyloxy, C₃₋₁₀ cycloalkyloxy, C₅₋₇ cycloalkenyloxy, aryloxy, heteroaryloxy, (C₂₋₄ alkenyl) C₁₋₃ alkyloxy, (C₂₋₄ alkynyl) C₁₋₃ alkyloxy, (aryl) Cil alkyloxy ₋₃, (heteroaryl) C₁₋₃ alkyloxy, C₁₋₄ alkylsulfanyl, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₃₋₁₀ cycloalkylsulfanyl, C₃₋₁₀ cycloalkylsulfinyl, C₅₋₁₀ cycloalkylsulfonyl, C₅₋₁₀ cycloalkenylsulfanyl, C₅₋₁₀ cycloalkenylsulfinyl , C₅₋₁₀ cycloalkenylsulfonyl, arylsulfanyl, arylsulfinyl, arylsulfonyl, amino, hydroxy, cyano and nitro; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of R³ are optionally partially or completely fluorinated and are optionally mono- or disubstituted with identical or different substituents selected from chlorine, hydroxy, C₁₋₃ alkoxy and alkyl C₁₋₃, and in the groups or the cycloalkyl and cycloalkenyl portions of R³, one or two methylene groups are optionally independently replaced with O, S, CO, SO or SO₂, and in the N-heterocycloalkyl groups or portions of R³, a methylene group is optionally replaced by CO or SO₂; R⁴ is a member selected from the group consisting of hydrogen, halo, cyano, nitro, hydroxy, C₁₋₃ alkyl, C₃₋₁₀ cycloalkyl, C₁₋₃ alkyloxy or C₃₋₁₀ cycloalkyloxy, where the alkyl and cycloalkyl groups or portions of R⁴ are optionally mono- or polysubstituted with fluorine, and when R³ and R⁴ are joined by adjacent C atoms of the phenyl ring, R³ and R⁴ optionally join to form a C₃₋₅ alkylene, Cque alkenylene or butadienylene bridge which is optionally partially or completely fluorinated and is optionally mono- or disubstituted with identical or different substituents selected from chloro, hydroxy, C₁₋₃ alkoxy and C₁₋₃ alkyl, and where one or two methylene groups are optionally independently replaced with O, S, CO, SO, SO₂ or NRᵇ, and where one or two methine groups are optionally replaced by N; R⁵ is a member selected from the group consisting of hydrogen, halo, cyano, nitro, hydroxy, C₁₋₃ alkyl, C₃₋₁₀ cycloalkyl and C₁₋₃ alkyloxy, where the alkyl and cycloalkyl groups or portions of R⁵ are optionally mono- or fluorinated polysubstituted; each R⁶, R⁷, R⁸ and R⁹ are independently selected from the group consisting of hydroxy, (C₁₋₁₈ alkyl) carbonyloxy, (C₁₋₁₈ alkyl) oxycarbonyloxy, arylcarbonyloxy, aryl- (C₁₋₃ alkyl) carbonyloxy, (C₃ cycloalkyl ₋₁₀) carbonyloxy, hydrogen, halo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (C₃₋₁₀ cycloalkyl), (C₅₋₇ cycloalkenyl) C₁₋₃ alkyl, C₁₋₃ arylalkyl , C₁₋₃ heteroaryl-alkyl, C₁₋₆ alkyloxy, C₂₋₆ alkenyloxy, C₂₋₆ alkynyloxy, C₃₋₇ cycloalkyloxy, aryloxy, heteroaryloxy, (C₃₋₇ cycloalkyl) C₁₋₃ alkyloxy, (cycloalkenyl C₅₋₇) C₁₋₃ alkyloxy, C₁₋₃ aryl-alkyloxy, C₁₋₃ heteroarylalkyloxy, aminocarbonyl, hydroxycarbonyl, (C₁₋₄ alkyl) aminocarbonyl, di- (C₁₋₃ alkyl) aminocarbonyl, (C₁₋₄ alkyloxy) carbonyl , aminocarbonyl-C₁₋₃ alkyl, (C₁₋₄ alkyl) ami nocarbonyl C₁₋₃ alkyl, di- (C₁₋₃ alkyl) aminocarbonyl C₁₋₃ alkyl, hydroxycarbonyl C alquilo alkyl, (C alquilo alkyloxy) carbonyl C₁₋₃ alkyl, (C₃₋₇ cycloalkyloxy) C alquilo alkyl ₋₃, (C₅₋₇ cycloalkenyloxy) C₁₋₃ alkyl, aryloxy-C₁₋₃ alkyl, heteroaryloxy-C₁₋₃ alkyl, alkylsulfonyloxy C₁₋₄, arylsulfonyloxy, aryl-C₁₋₃-alkyl sulfonyloxy, trimethylsilyloxy, t-butyldimethylsilyloxy, and cyano; wherein the alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups or portions of R⁶, R⁷, R⁸ and R⁹ are optionally partially or completely fluorinated and are optionally mono- or disubstituted with identical or different substituents selected from the group consisting of chlorine, hydroxy, C₁₋₃ alkoxy and C₁₋₃ alkyl, and in the cycloalkyl and cycloalkenyl groups or portions of R⁶, R⁷, R⁸ and R⁹, one or two methylene groups are optionally independently replaced with NRᵇ, O, S , CO, SO or SO₂; each Rᵃ is a member independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl and (C₁₋₄ alkyl) carbonyl, where the alkyl and cycloalkyl groups or portions of Rᵃ are optionally partially fluorinated or complete; each Rᵇ is a member independently selected from the group consisting of H, C₁₋₄ alkyl and (C₁₋₄ alkyl) carbonyl, where the Rᵇ alkyl groups or portions are optionally partially or completely fluorinated; each Rᶜ is a member independently selected from the group consisting of H, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, CHRᵈRᵉ, SO₂Rᵈ, C (O) ORᵈ and C (O) NRᵈRᵉ, where the alkyl and cycloalkyl groups of Rᶜ are optionally partially or completely fluorinated; and each Rᵈ and Rᵉ independently represents H or C₁₋₆ alkyl, where the alkyl groups of Rᵈ and Rᵉ are optionally partially or completely fluorinated; and its salts acceptable for pharmaceutical use. |
| priorityDate | 2007-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.